V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Repligen Executive Compensation (FY25)

RGEN · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Olivier Loeillot
Latest say-on-pay support
=
May 14, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Repligen brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): May 15, 2026
17 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Repligen brief$1,500Get the executive brief
Velarion Member, one year
411 figures on this page: 400 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Olivier Loeillot: $7,184,359 → $6,114,771 (14.9% lower)
CEO pay ratio: 69:1 → 82:1 (18.8% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Repligen's chief executive and what were they paid?
Olivier Loeillot, President and Chief Executive Officer, received $6,114,771 in total compensation for fiscal 2025. Loeillot's total moved 14.9% lower from the $7,184,359 reported for fiscal 2024.
What was Repligen's say-on-pay result?
The say-on-pay proposal drew 97.0% of votes cast including abstentions in favor at the meeting held May 14, 2026 for fiscal 2025.
Which companies are in Repligen's peer group?
Companies named in the disclosed peer group include 10x Genomics, Inc., Azenta, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation and Bruker Corporation, among others.
What is Repligen's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 82:1, against median employee compensation of $74,954.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Tony Hunt
President and CEO
◇—◇◇◇—◇◇
Jon Snodgres
Chief Financial Officer
◇◇◇◇◇—◇◇
James Bylund
Chief Operating Officer
◇◇◇◇◇—◇◇
Ralf Kuriyel
Senior Vice President of Research and Development
◇◇◇◇◇—◇◇
Christine Gebski
Senior Vice President of Filtration & Chromatography
◇◇◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Tony Hunt
Chief Executive Officer and Director
◇—◇◇——◇◇
Olivier Loeillot
President and Chief Commercial Officer
◇◇◇◇———◇
James Bylund
Chief Operating Officer
◇—◇◇——◇◇
Jon Snodgres
Former Chief Financial Officer
Departed during or after this year
◇—◇◇———◇
Jason Garland
Chief Financial Officer
◇◇◇◇——◇◇
Ralf Kuriyel
Senior Vice President, Research and Development
◇—◇◇——◇◇
Christine Gebski
Senior Vice President, Filtration and Chromatography
◇—◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Tony Hunt
Executive Chair of the Board and Former Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Olivier Loeillot
President and Chief Executive Officer
◇—◇◇◇—◇◇
James Bylund
Chief Operating Officer
◇—◇◇◇—◇◇
Jason Garland
Chief Financial Officer
◇—◇◇◇—◇◇
Ralf Kuriyel
Senior Vice President, Research and Development
◇—◇◇◇—◇◇
Christine Gebski
Former Senior Vice President, Filtration and Chromatography
Departed during or after this year
◇◇◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Olivier Loeillot
President and Chief Executive Officer
◇—◇◇◇—◇◇
Jason Garland
Chief Financial Officer
◇—◇◇◇—◇◇
James Bylund
Chief Operating Officer
◇—◇◇◇—◇◇
Ralf Kuriyel
Senior Vice President, Research and Development
◇—◇◇◇—◇◇
Brian Douglass
Senior Vice President, Chief Product Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brian DouglassRSU◇——◇——◇
Brian DouglassPSU◇◇◇—◇—◇
Brian DouglassRSU◇——◇——◇
Brian DouglassOPTION◇——◇—◇◇
James BylundRSU◇——◇——◇
James BylundPSU◇◇◇—◇—◇
James BylundPSU◇◇◇—◇—◇
James BylundOPTION◇——◇—◇◇
Jason K. GarlandPSU◇◇◇—◇—◇
Jason K. GarlandRSU◇——◇——◇
Jason K. GarlandOPTION◇——◇—◇◇
Olivier LoeillotRSU◇——◇——◇
Olivier LoeillotPSU◇◇◇—◇—◇
Olivier LoeillotOPTION◇——◇—◇◇
Ralf KuriyelPSU◇◇◇—◇—◇
Ralf KuriyelRSU◇——◇——◇
Ralf KuriyelPSU◇◇◇—◇—◇
Ralf KuriyelOPTION◇——◇—◇◇
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Ralf KuriyelPSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/27/2034
PSU◇◇——
Option◇—◇3/2/2033
Option◇—◇3/1/2035
Jason GarlandRSU◇◇——
Option◇—◇9/25/2033
PSU◇◇——
RSU◇◇——
Option◇—◇3/1/2035
Option◇—◇2/27/2034
PSU◇◇——
RSU◇◇——
James BylundPSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇3/2/2033
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇2/27/2034
RSU◇◇——
Olivier LoeillotPSU◇◇——
PSU◇◇——
Option◇—◇9/3/2034
Option◇—◇10/2/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/27/2034
Option◇—◇3/1/2035
PSU◇◇——
Brian DouglassRSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇12/31/2035
Option◇—◇5/7/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Brian Douglass
Senior Vice President, Chief Product Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
James Bylund
Chief Operating Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Jason Garland
Chief Financial Officer · Employment agreement · citing a 2023 filing
Non-compete period◇
Non-solicit period◇
Olivier Loeillot
President and Chief Executive Officer · Employment agreement · citing a 2024 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Ralf Kuriyel
Senior Vice President, Research and Development · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Tony J. Hunt
—————◇◇
Karen A. Dawes
Lead independent director
◇◇◇———◇
Glenn P. Muir
◇◇◇———◇
Margaret A. Pax
◇◇◇———◇
Martin Madaus
Board chair
◇◇◇———◇
Nicolas M. Barthelemy
◇◇◇———◇
Rohin Mhatre
◇◇◇———◇
Carrie Eglinton Manner
◇◇◇———◇
Konstantin Konstantinov
◇◇◇———◇
Olivier Loeillot served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 10x Genomics, Inc. TXG
  • Azenta, Inc. AZTA
  • Bio-Rad Laboratories, Inc. BIO
  • Bio-Techne Corporation TECH
  • Bruker Corporation BRKR
  • Halozyme Therapeutics, Inc HALO
  • Insulet Corporation PODD
  • Maravai LifeSciences Holdings, Inc. MRVI
  • Medpace Holdings, Inc. MEDP
  • Mesa Laboratories, Inc. MLAB
  • Natera, Inc. NTRA
  • Neogen Corporation NEOG
  • NovaCure Limited, Inc. symbol not shown
  • Quanterix Corporation QTRX
  • Waters Corporation WAT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 14, 2026=◇◇◇
2024May 15, 2025=◇◇◇
2023May 16, 2024=◇◇◇
2022May 18, 2023=◇◇◇
2021May 26, 2022=◇◇◇
2020May 13, 2021=◇◇◇
2019May 13, 2020=◇◇◇
2018May 15, 2019=◇◇◇
2017May 16, 2018=◇◇◇
2016May 18, 2017=◇◇◇
2015May 11, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Olivier Loeillot (President and Chief Executive Officer), FY2025 total compensation $6,114,771 (base salary $860,000) [exec_comp, SEC accession 0001193125-26-140115, filed 2026-04-02]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Repligen files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Repligen disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Repligen sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Repligen's disclosed peer group is defensible, who names Repligen back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
411 figures on this page: 400 cited to the filing that reported them, 11 calculated from figures it prints.
400 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001193125-26-225380
    Proposal 3 - Advisory Vote on Compensation of the Named Executive Officers For Against Abstain Broker Non-Votes
  2. 0001193125-26-140115
    CEO Pay Ratio · Compensation Discussion and Analysis · Director Compensation · Executive Compensation Tables · and 1 more section
  3. 0000950170-25-072664
    Proposal 3 - Advisory Vote on Compensation of the Named Executive Officers The compensation paid to the Company’s named executive officers was approved on an advisory basis.
  4. 0000950170-25-051141
    Executive Compensation Tables
  5. 0001193125-24-141217
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-24-083397
    EXECUTIVE COMPENSATION TABLES · Executive Compensation Tables · Summary Compensation Table
  7. 0001193125-23-150037
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-23-097893
    Executive Compensation Tables
  9. 0001193125-22-165344
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-21-166003
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-20-143990
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-19-152725
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001193125-18-170961
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001193125-17-179814
    Item 5.07 Submission of Matters to a Vote of Security Holders
  15. 0001193125-16-589062
  16. 0001193125-23-233111
    EX-10.12
  17. 0000950170-24-087981
    EX-10.11
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Repligen executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/RGEN (accessed 2026).
Short form: data: Velarion

The Repligen brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
17 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Repligen and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Repligen discloses

The companies named in RGEN's own disclosed peer group.

10x Genomics, Inc.Azenta, Inc.Bio-Rad Laboratories, Inc.Bio-Techne CorporationBruker CorporationHalozyme Therapeutics, IncInsulet CorporationMaravai LifeSciences Holdings, Inc.Medpace Holdings, Inc.Mesa Laboratories, Inc.Natera, Inc.Neogen CorporationQuanterix CorporationWaters Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy